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Abstract
We evaluated spine bone mineral density (BMD) in Brazilian children
with juvenile systemic lupus erythematosus (JSLE) in order to detect
potential predictors of reduction in bone mass. A cross-sectional study
of BMD at the lumbar spine level (L2-L4) was conducted on 16 female
JSLE patients aged 6-17 years. Thirty-two age-matched healthy girls
were used as control. BMD at the lumbar spine was measured by dual-
energy X-ray absorptiometry. Weight, height and pubertal Tanner
stage were determined in patients and controls. Disease duration,
mean daily steroid doses, mean cumulative steroid doses and JSLE
activity measured by the systemic lupus erythematosus disease activ-
ity index (SLEDAI) were determined for all JSLE patients based on
their medical charts. All parameters were used as potential determi-
nant factors for bone loss. Lumbar BMD tended to be lower in the
JSLE patients, however, this difference was not statistically signifi-
cant (P = 0.10). No significant correlation was observed in JSLE girls
between BMD and age, height, Tanner stage, disease duration, corti-
costeroid use or disease activity. We found a weak correlation be-
tween BMD and weight (r = 0.672). In the JSLE group we found no
significant parameters to correlate with reduced bone mass. Disease
activity and mean cumulative steroid doses were not related to BMD
values. We did not observe reduced bone mass in female JSLE.
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Introduction
Osteoporosis is a major public health prob-
lem affecting postmenopausal women and
older persons in general. Due to improve-
ments in instrumentation we can now detect
this condition in children.
Significant osteopenia has been detected
in children with diseases such as juvenile
dermatomyositis, juvenile rheumatoid arthri-
tis and juvenile systemic lupus erythemato-
sus (JSLE) (1-5). Multiple causes have been
proposed to contribute to osteopenia, includ-
ing limited physical activity, immobility, lim-
ited exposure to sunlight, systemic inflam-
mation, corticosteroid use, delay in pubertal
development, inadequate dietary intake of
calcium and vitamins, and renal insufficiency
(3,5-10). Although there is no consensus
about the extent of the impact of these fac-
tors on bone mineral density (BMD) in chil-
dren with rheumatic diseases, it is important
to understand their implications in order to
plan further strategies to prevent and treat
bone disease in these children. The objective
of the present study was to assess BMD in
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normal and JSLE Brazilian children in order
to determine potential predictors of bone
mass modifications.
Material and Methods
Patients
We studied 16 girls aged 6 to 17 years
with JSLE diagnosed according to the Ameri-
can College of Rheumatology criteria for the
classification of systemic lupus erythemato-
sus (SLE) (11). As a control group we evalu-
ated 32 age-matched healthy girls from the
community. The study protocol was approved
by the Ethics Committee of Universidade
Federal de São Paulo and written informed
consent was obtained from all parents or
guardians.
Weight and height were measured in pa-
tients and controls using an anthropometric
balance. Tanner stage was assigned by a
pediatrician as determined by physical ex-
amination. Patients were classified into two
groups: i) group 1, consisting of girls within
the G1-G2 Tanner range, and ii) group 2,
consisting of G3-G5 girls. This division was
based on the fact that patients with Tanner
G3 or higher usually present increased bone
mass (12). Duration of disease was consid-
ered as the period of time from the first
clinical manifestations to the evaluation by
densitometry. Mean daily steroid doses and
mean cumulative steroid doses of prednisone
were calculated from medical charts for ev-
ery patient.
For the children with JSLE, medical charts
were reviewed and current disease activity
was assessed by the SLE disease activity
index (SLEDAI). We considered active dis-
ease to be present when SLEDAI was >10.
Dual-energy X-ray absorptiometry
BMD at the lumbar spine level (L2-L4)
was measured in all subjects by dual-energy
X-ray absorptiometry using a LUNAR DPX
densitometer (Lunar Radiation Corporation,
Madison, WI, USA). In our Densitometer
Unit this instrument has a coefficient of
variation of 2.0% at the lumbar spine in
children.
Statistical analysis
The Student t-test was used to compare
BMD of patients and controls. The 2-test
was used to compare BMD of controls and
JSLE patients with Tanner stage. In the JSLE
group, Pearson’s correlation coefficient was
used to detect potential associations between
BMD and anthropometric measures, disease
duration, mean daily steroid doses and mean
cumulative steroid doses. The Student t-test
was also used to compare BMD of patients
with Tanner stage and disease activity. All
statistical analyses were performed using
the SPSS software version 8.0. A P value of
<0.05 was considered to be statistically sig-
nificant.
Results
Sixteen female patients with JSLE and
32 aged-matched healthy girls were included
in this study. Data considering age, weight,
height, disease duration, cumulative and daily
doses of prednisone and BMD values for
both groups are shown in Table 1. Mean
duration of disease was 3.9 ± 2.7 years.
Most patients had been taking corticoste-
roids during the course of their disease. All
patients with JSLE were treated with corti-
costeroids and at the time of evaluation all
but one were taking this medication. The
mean daily steroid dose was 0.54 ± 0.42 mg
kg-1 day-1 and the mean cumulative steroid
dose was 14.2 ± 11.3 g. In the JSLE group, 4
patients were in stage G1-G2 and 12 were in
stage G3-G5. In the control group, 10 indi-
viduals were in stage G1-G2 and 22 were in
stage G3-G5. Pubertal development did not
differ significantly between the two groups.
Mean SLEDAI score for the JSLE group
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was 7.7 (range: 0-28). According to the
SLEDAI, 11 children presented inactive dis-
ease (SLEDAI between 1 and 10) and 5 had
active disease (SLEDAI higher than 10).
Except for height, the two groups were
similar (age, weight, and Tanner stage) and
did not show any statistically significant
difference. As can be seen in Table 1, BMD
values in the JSLE group were not statisti-
cally different compared with those seen in
the control group (P = 0.10).
In the JSLE group, we did not observe a
significant correlation between BMD and
age, height, disease duration or corticoster-
oid use. A statistically significant correla-
tion was observed between BMD and weight
(r = 0.672). There were no significant BMD
differences between JSLE stages G1-G2 and
stages G3-G5 (0.839 vs 0.848 g/cm2) or
between patients with and without disease
activity.
Discussion
Although some information concerning
BMD in adults with SLE is available (13-
15), few data on children and adolescents
have been reported (1,16,17). Steroids are a
mainstay of drug therapy in SLE and are a
well-recognized cause of osteoporosis in
rheumatoid arthritis and other conditions such
as asthma (18-21). Adult patients with SLE
present low bone mass at peripheral and
axial skeletal sites mainly related to steroid
treatment (22).
Our results did not demonstrate that chil-
dren with JSLE present a reduced bone mass
at the lumbar spine level compared to healthy
children. JSLE patients usually do not pres-
ent significant muscle or joint involvement,
which, in our opinion, would be the most
important determinant factor for a reduction
of bone mass in diseases like juvenile rheu-
matoid arthritis and juvenile dermatomyosi-
tis. Differently from adult patients with SLE,
our study showed that in children with JSLE
there is no significant correlation between
bone mass and steroid use. The Student t-test
did not demonstrate a clear impact of corti-
costeroid use on lupus children’s BMD. An
influence of corticotherapy was not observed
probably due to the period between the be-
ginning of the treatment and the posterior
study enrollment. In other words, many pa-
tients were not already taking high doses of
corticosteroids at the beginning of the study.
Some other studies have demonstrated a role
of steroids in determining bone loss in JSLE
children. However, Falcini et al. (17) ob-
served a reduction in both lumbar spine BMD
and calcaneal ultrasound measurements in
53 patients affected by juvenile rheumatoid
arthritis (N = 29), JSLE (N = 13) and juve-
nile dermatomyositis (N = 11) compared
with a control group. All patients with JSLE
were taking corticosteroids. Using a longitu-
dinal study design, Trapani et al. (16) re-
ported that JSLE children (N = 20) had the
same BMD values when compared with a
control group at baseline and after a one-
year follow-up. Only in those patients aged
19 to 25 years was BMD significantly lower
than in controls. However, the authors dem-
onstrated that the mean yearly BMD loss in
the steroid-treated patients was 0.031 g/cm2
(3.5%) vs 0.005 g/cm2 (0.5%) in those who
had not taken steroids.
Peak bone mass plays an important role
Table 1. Demographic, anthropometric and clinical characteristics and bone mineral
density (BMD) of patients with juvenile systemic lupus erythematosus (JSLE) and
controls.
JSLE patients Control
Age (years) 13.3 ± 3.1 13.0 ± 3.0
Weight (kg) 37.3 ± 9.5 42.8 ± 10.6
Height (cm) 140.7 ± 13.1* 150.5 ± 12.3
Disease duration (years) 3.9 ± 2.7 -
Disease activity (SLEDAI) 7.7 -
Daily steroid doses (mg kg-1 day-1) 0.54 ± 0.42 -
Cumulative steroid doses (g) 14.2 ± 11.3 -
BMD (g/cm2) 0.846 ± 0.199 0.946 ± 0.197
Data are reported as means ± SD for 16 patients and 32 controls. SLEDAI = systemic
lupus erythematosus disease activity index.
*P = 0.01 compared to control group (Student t-test).
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in determining the risk of developing os-
teoporotic fractures in adulthood. Since most
bone mass is acquired during the pre- and
perimenarcheal period, the importance of
such event in growing girls should not be
undervalued (23,24). During puberty, the
total increase in BMD is higher than that
during the preceding 10 years. The most
important increase in lumbar spine BMD
was found in pubertal stage 4 for girls and
boys (12). It is during this stage of puberty
that deceleration of the growth spur occurs
and adult levels of sex steroids can be at-
tained (12). In our study, we did not find a
significant correlation between bone loss
and pubertal stage. However, JSLE patients
who were in stages G1-G2 presented lower
BMD than patients in stages G3-G5. Our
results indicated some increment in bone
mass as a function of pubertal development
even in patients with an important reduction
in bone density.
We showed that weight is significantly
correlated with BMD in JSLE, in agreement
with other studies showing that weight is the
best predictor of bone mass in healthy chil-
dren (25,26).
Duration of disease was not related to
BMD, as previously demonstrated in adult
patients with SLE (22). However, there are
many disease-related variables that could
play a role in determining BMD in patients
with JSLE (27-30).
Disease activity and steroid treatment
did not correlate with BMD values in these
patients. A larger number of patients would
be required to support a statistically signifi-
cant reduction in BMD.
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